Unmasking neurobiological commonalities between addictive disorders and impulse control disorders in Parkinson’s disease

Ramdave, Swathi; Dawson, Andrew; Carter, Adrian; Dissanayaka, N.

doi:10.1007/s11682-019-00041-7

Cited by 4 publications

(4 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years neuroimaging, particularly that which is focused on the dopaminergic system, has significantly contributed to the knowledge of neurobiological factors for ICDs (2, 7, 8, 81, 82) (see Tables 5A–D).…”

Section: Neuroimaging In Pd Patients With Icdsmentioning

confidence: 99%

Impulse Control Disorders in Parkinson's Disease. A Brief and Comprehensive Review

Gatto

Aldinio

2019

Front. Neurol.

View full text Add to dashboard Cite

Impulse control and related disorders (ICDs-RD) encompasses a heterogeneous group of disorders that involve pleasurable behaviors performed repetitively, excessively, and compulsively. The key common symptom in all these disorders is the failure to resist an impulse or temptation to control an act or specific behavior, which is ultimately harmful to oneself or others and interferes in major areas of life. The major symptoms of ICDs include pathological gambling (PG), hypersexualtiy (HS), compulsive buying/shopping (CB) and binge eating (BE) functioning. ICDs and ICDs-RD have been included in the behavioral spectrum of non-motor symptoms in Parkinson's disease (PD) leading, in some cases, to serious financial, legal and psychosocial devastating consequences. Herein we present the prevalence of ICDs, the risk factors, its pathophysiological mechanisms, the link with agonist dopaminergic therapies and therapeutic managements.

show abstract

Section: Neuroimaging In Pd Patients With Icdsmentioning

confidence: 99%

Impulse Control Disorders in Parkinson's Disease. A Brief and Comprehensive Review

Gatto

Aldinio

2019

Front. Neurol.

View full text Add to dashboard Cite

show abstract

“…Thus, our study confirms studies which showed close similarities between substance use disorder and PD-srICD (Probst and van Eimeren 2013 ; Limotai et al 2012 ; e.g., Dagher and Robbins 2009 ; Voon et al 2010b ). Therefore, our results may reflect the behavioural level of cerebral circuits reward circuits in addiction (Navalpotro-Gomez et al 2020 ; Ramdave et al 2020 ). This can be explained by role of dopamine transmission in learning.…”

Section: Discussionmentioning

confidence: 73%

“…ICD behaviours in PD patients often resemble addiction (Probst and van Eimeren 2013 ; Limotai et al 2012 ; e.g., Dagher and Robbins 2009 ; Voon et al 2010b , Ramdave et al 2020 ). While PD patients without ICD are known to show less sensation seeking/novelty orientation (Djamshidian et al 2011b ) and more harm avoidance (Tomer and Aharon-Peretz 2004 ), PD patients with ICD behaviours are more prone to risk-taking behaviour and show a preference for uncertainty, more perseverative responses, and a heightened drive to engage in gambling and gambling-related behaviours (Marques et al 2018 ).…”

Section: Introductionmentioning

confidence: 99%

Characteristics of behavioural addiction in Parkinson’s disease patients with self-reported impulse control disorder and controls matched for levodopa equivalent dose: a matched case–control study

et al. 2023

View full text Add to dashboard Cite

Impulse control disorders (ICD) in Parkinson’s disease (PD) frequently occur, not always as a direct consequence of dopaminergic medication. This study investigated premorbid personality traits and behavioural characteristics in non-demented PD patients with self-reported symptoms of ICD (PD-srICD). From a total of 200 non-demented PD patients who filled out questionnaires assessing symptoms and severity of ICD, those were classified as PD-srICD (n = 32) who reported current occurrence of at least one compulsive behaviour (gambling, sexual behaviour, buying behaviour, or eating). As a control group, 32 patients with no self-reported ICD symptoms were matched for levodopa equivalent daily dose. The demographic, clinical, and premorbid personality profiles were compared between both groups. Frequency of psychological characteristics indicating substance use disorder was evaluated in patients with PD-srICD. Patients with PD-srICD were more frequently male, younger at examination, had earlier PD onset, more depression, higher non-motor burden, less quality of life (p < 0.05, respectively), and more frequently reported premorbid sensation seeking/novelty orientation (p = 0.03) and joyful experience of stress (p = 0.04) than patients in the control group. Of patients with PD-srICD, 90.6% reported at least one behavioural characteristic of substance use disorder, most frequently positive expectations following ICD behaviour and illusional beliefs about its behavioural control. Signs of addiction were common among patients with PD-srICD. Therefore, the profile of psychological characteristics in patients with PD-srICD resembled that of patients with substance use disorder. It can be concluded that dopamine replacement therapy (DRT) alone does not account for PD-srICD and that thorough psychological diagnostics are recommended.

show abstract

“…In comparison, there is emerging consensus of dopaminergic agents altering motor or cognitive/attentional control, thereby increasing choice impulsivity [47]. Thus, impulse control problems such as substance use occur in a subset of susceptible patients with Parkinson's disease with dopamine replacement therapy, which may be due to deficits in dopaminergic receptor expression, connectivity patterns in cortico-striatal circuitry and exaggerated neural responses to cue exposure [48]. Those Parkinson disease individuals who report greater levels of depression and show a nontremor phenotype seem to be susceptible to boosting of reward-versus punishment-based choice by medication, which may reflect an underlying dysregulation of the mesolimbic dopamine system [49 ▪▪ ].…”

Section: Neurological Disorders and Substance Usementioning

confidence: 99%

Neural substrates of substance use disorders

Paulus¹

2022

Current Opinion in Neurology

View full text Add to dashboard Cite

Purpose of reviewSubstance use disorders account for a tremendous burden to society, yet despite substantial progress in basic studies, our understanding of the brain-basis of these disorders is still emerging. This review summarizes the recent findings of neuroimaging studies with substance use disorder individuals.Recent findingsResting-state functional connectivity studies support for some but not all substances of abuse and disruption in executive control. Structural neuroimaging findings point towards reduced subcortical volumes, which may emerge as an interaction between preexisting factors and recent substance use. Longitudinal studies implicate some of the same core brain structures and their functional role that have also been identified via case–control studies. Finally, meta-analyses support the idea of dysregulation of cortical control over subcortical salience processing.SummaryAlthough progress has been made and there is both structural and functional imaging evidence of an imbalance between brain structures involved in executive control and salience processing, there is emerging evidence that brain-behaviour relationships, which are core to discovering the neural processes that lead to and maintain substance use, are small and require larger consortia that prospectively examine individuals with substance use disorder.

show abstract

Unmasking neurobiological commonalities between addictive disorders and impulse control disorders in Parkinson’s disease

Cited by 4 publications

References 81 publications

Impulse Control Disorders in Parkinson's Disease. A Brief and Comprehensive Review

Impulse Control Disorders in Parkinson's Disease. A Brief and Comprehensive Review

Characteristics of behavioural addiction in Parkinson’s disease patients with self-reported impulse control disorder and controls matched for levodopa equivalent dose: a matched case–control study

Neural substrates of substance use disorders

Contact Info

Product

Resources

About